Navigation Links
Study Suggests Invega Helps Patients With Schizophrenia Maintain,,,Symptom Control

ing," concluded Dr. Meltzer.


    Tolerability



    - The safety profile was generally consistent with the 6-week data.



    - The most common treatment-emergent adverse events (TEAEs)***, that



      occurred at a rate of 10 percent or more were: extrapyramidal disorder



      (movement disorder) (25%), insomnia (14%), headache (12%), and akathisia



      (restlessness) (11%).



    - TEAEs occurred in a total of 76% of participants, although only 7



      percent of patients in the trial withdrew from the study due to adverse



      effects. Total mean change in bodyweight during the 52-week OLE was an



      average of 1.1 kg.



INVEGA(TM) (paliperidone) Extended-Release Tablets is approved for the treatment of schizophrenia in the U.S.

IMPORTANT SAFETY INFORMATION FOR INVEGA(TM)

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA (paliperidone) is not approved for the treatment of patients with Dementia-Related Psychosis.

The most common side effects that occurred with INVEGA during the six week placebo-controlled trials were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness).

One risk of INVEGA is that it may change your heart rhythm. This effect is potentially serious, and you should talk to your doctor about any current or past heart problems. Some medications may interact with INVEGA. Please inform your healthcare professional of any medications or supplements that you are taking.

A rare but serious side effect that has been reported with this kind of medicine, including INVEGA, is known as neuroleptic malignant syndrome (NMS). NMS is characterized by muscle rigidity, fever and can be serious.

You may have heard the term "tardive dyskinesia." These are usuall
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/31/2015)... -- Boston Children,s Hospital physicians report the first cases ... anatomy before undergoing high-risk brain procedures. The four ... brain,s blood vessels) that posed special treatment challenges. ... Journal of Neurosurgery: Pediatrics , the physicians describe ... to create custom, high-fidelity models of the children,s ...
(Date:7/31/2015)... Ore., July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... testing services to healthcare insurers and physician groups, today ... 30, 2015. "In the second quarter ... year revenue growth of 54%, quarter over quarter revenue ... the installed base of FloChec® units of 18%," said ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation ... of heart valves and hemodynamic monitoring, today announced that ... of Directors. "Bob is an ardent champion for ... true privilege to have him on Edwards, board as we ... , Edwards, chairman and CEO.  "Bob has provided a valuable ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... March 14, 2012 Paradigm Spine, LLC, a leading ... addition of key strategic personnel to strengthen operations and ... Guntmar Eisen has been promoted to the position of ... Paradigm Spine, LLC, he has extensive operating experience in ...
... TAMPA, Fla., March 14, 2012   ISPE announced today ... upcoming "Redefining the ,C, in ,CGMP," Conference in Baltimore, ... conference is the first joint ISPE-FDA conference focused on ... The conference will feature a new ...
Cached Medicine Technology:Paradigm Spine, LLC Announces Strategic Promotions and Hiring of Key Personnel to Ensure Long-Term Growth and Success 2ISPE Announces FDA to Co-Sponsor June CGMP Conference in Baltimore 2
(Date:8/3/2015)... ... August 03, 2015 , ... The ... (ICC) announce an agreement to collaborate across a wide range of initiatives ... building code knowledge among architects. , “Our combined membership, consisting of practicing design ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
Breaking Medicine News(10 mins):Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... ARLINGTON, Va., Dec. 2 From more than 1,100 photos ... and peace, the LIFE Foundation has selected six winners in ... flickr.com. The winning photos can be viewed in a video ... . , Contestants submitted one photo and a caption ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , WASHINGTON and REDMOND, Wash., Dec. 2 ... announced the companies will collaborate to give caregivers single-point access ... after patients leave the hospital and to give patients and ... Living is the first post-acute care organization to adopt Microsoft ...
... to life span in males , WEDNESDAY, Dec. 2 (HealthDay ... and other mammals and could help explain why females tend ... researchers found that mice created using two female genomes -- ... than mice created from the normal combination of a male ...
... found drinking five or more per week prior to ... (HealthDay News) -- Women who drink five or more ... increase their risk of developing diabetes during pregnancy, a ... association with other chronic metabolic problems," said study author ...
... , LONDON, Dec. ... of improved therapies to treat lifestyle disorders. In the near ... witness enhanced therapies and novel drugs to treat such conditions ... ) , New analysis from Frost & Sullivan ( http://www.pharma.frost.com ...
Cached Medicine News:Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 2Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 4Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:Sugary Colas Tied to Gestational Diabetes 2Health News:Sugary Colas Tied to Gestational Diabetes 3Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 2Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: